martes, 30 de abril de 2024

FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer

No hay comentarios:

Publicar un comentario